AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01310673
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet QD for 10 days, followed by delayed allopurinol 300mg po QD days 11-30.~Indomethacin 50mg TID for 10 days. Colchicine 0.6mg po Bid or QD, as tolerated for 90 days.
Trial: NCT03219931
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is the placebo product containing a similar product without bifidobacterium inside.
Trial: NCT03242460
Drug: Cyclophosphamide 400mg
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 400mg Days 1, 8, 15
Trial: NCT00085774
Drug: placebo aerosol by HFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo HFA
Trial: NCT03680573
Drug: Control: Lacated Ringers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This site will serve as the control site
Trial: NCT03728634
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator calculated volume to match ION-682884 administered SC
Trial: NCT03680573
Drug: NG Nitro L Arginine Methyl Ester
RxNorm normalized name: methyl L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min
Trial: NCT03680573
Drug: Acetyl-ß-methylcholine chloride
RxNorm normalized name: Acetyl-beta-methylcholine
DrugBank: Methacholine (DB06709)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mch is an acetylcholine analog that causes endothelial dependent vasodilation primarily through stimulation of NO production.
Trial: NCT04941339
Drug: MRG002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated intravenously
Trial: NCT01776463
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00973765
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 2 pills po BID x 7 days
Trial: NCT01457521
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen
Trial: NCT01190878
Drug: ISV-303
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.075% of bromfenac in DuraSite dosed QD
Trial: NCT01190878
Drug: ISV-303
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.075% of bromfenac in DuraSite dosed BID
Trial: NCT01190878
Drug: Xibrom™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.09% bromfenac dosed BID
Trial: NCT00233103
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03731988
Drug: MAL application
RxNorm normalized name: maleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
Trial: NCT03349515
Drug: Group B will receive three drops in each eye of ophthalmic balanced salt solution.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B will receive three drops in each eye of ophthalmic balanced salt solution. The eye drops will be administered by the study anesthesiologist. After application of either solution to the eyes of the patient, any change in ventilation can be detected and timed by observation of the capnography (end-tidal carbon dioxide) and direct observation of the chest wall with use of the iPhone stopwatch feature again. The capnograph is a standard monitor of respiration used during the administration of general anesthesia. Data collected at this time will include whether or not there was a change in respiration, what this change in respiration was, if assisted ventilation was required, how long assisted ventilation was required (if applicable), HR, BP, RR, SaO2 , ETCO2, InspSevo, and ExpSevo. This study intervention and data collection will take less than 5 minutes
Trial: NCT02943759
Drug: Neem leaf extract
RxNorm normalized name: neem leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A natural irrigant solution act as anti-inflammatory and anti bacterial
Trial: NCT02872467
Drug: Syntocinon treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 IU twice daily (A single dose will be delivered consisting of 6 intranasal insufflations (3 in each nostril) which is equivalent to a total of 24 international units (IU) of oxytocin twice daily).
Trial: NCT01085591
Drug: CB-183,315
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01085591
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05818618
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral gel applied locally on OLP lesions.
Trial: NCT02201238
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium
Trial: NCT02401295
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00653965
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04360044
Drug: THC ~5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 puffs of vaporized flower containing THC \~5%
Trial: NCT00005047
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00005047
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01335581
Drug: Retin-A and microdermabrasion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microdermabrasion and topical lightening agent regimen
Trial: NCT00242489
Drug: MK0663, etoricoxib / Duration of Treatment: Part I (6 weeks), Part II (8 weeks)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04360044
Drug: CBD ~12%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 puffs of vaporized flower containing CBD \~12%
Trial: NCT04360044
Drug: THC ~5% and CBD ~12%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 puffs of vaporized flower containing THC \~5% and CBD \~12%
Trial: NCT00072020
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00667810
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
Trial: NCT00242489
Drug: Placebo;Diclofenac 50mg(tid)/Duration of Treatment: Part I (Placebo) 6 weeks;Part II (Diclofenac) 8 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00361335
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Active MTX capsules, filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg MTX tablet, will be administered at the same dose as before the study entry.
Trial: NCT00361335
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution will be administered through IV infusion in Group V and oral placebo capsules (sham MTX) filled with microcrystalline cellulose (Avicel PH 102) will be administered in Group II and IV.
Trial: NCT03241342
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo study drug is identical in appearance to the GTx-024 study drug and contains polyethylene glycol 400 but not GTx-024.
Trial: NCT03445650
Drug: ADX-102 1% Topical Dermal Cream (reproxalap)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADX-102 1% Topical Dermal Cream administered approximately every 24 hours for 6 months.
Trial: NCT03445650
Drug: Vehicle of ADX-102 Topical Dermal Cream
RxNorm normalized name: Dermal-Soothe Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle of ADX-102 Topical Dermal Cream administered approximately every 24 hours for 6 months.
Trial: NCT00512993
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Infusion of zoledronic acid (4 mg) every 4 weeks for six doses, followed by every 3 months for 8 doses, followed by every 6 months for 5 doses
Trial: NCT03309007
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total daily dose titrated up to 1944 mg po q day over the course of 4 weeks and continued for a total exposure of 12 weeks.
Trial: NCT03318276
Drug: Rinexin® Tab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rinexin® Tab is administrated to patients with PAD for 12 weeks
Trial: NCT01295294
Drug: Mefenamic acid
RxNorm normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg 3 times daily per oral during bleeding/spotting episodes
Trial: NCT01295294
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 times daily per oral during bleeding/spotting episodes
Trial: NCT03261960
Drug: BLI4700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bowel preparation
Trial: NCT02963376
Drug: 0.10 mL/kg DDFPe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.10 mL/kg based on patient body weight in kilograms (kg).
Trial: NCT01695746
Drug: C.E.R.A.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receiving 0.6 mcg/kg of C.E.R.A. once every two weeks for correction of anemia and conversion to C.E.R.A. dose 120, 200, or 360 mcg either once monthly; or 60, 100, or 180 mcg once every 2 weeks for maintenance of Hb according to local clinical practice or prescribing information will be observed.
Trial: NCT02963376
Drug: 0.10 mL/kg Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.10 mL/kg is based on patient body weight in kilograms (kg).
Trial: NCT00755859
Drug: steroids plus azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for six months
Trial: NCT00755859
Drug: steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day for six months
Trial: NCT03979781
Drug: tailored antiplatelet selection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antiplatelet selection guided by platelet function phenotype and/or key pharmacogene genotypes
Trial: NCT03709823
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg cellulose powder to match final weight of the cytisine tablet
Trial: NCT02960919
Drug: oral amoxicillin or parenteral ampicillin/ penicillin and gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02960919
Drug: gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03939884
Drug: Voltaren Topical
RxNorm normalized name: Voltaren Topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
Trial: NCT02963376
Drug: 0.17 mL/kg DDFPe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.17 mL/kg based on patient body weight in kilograms (kg).
Trial: NCT04163978
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: in situ 240mL nitric oxide releasing sinus irrigation solution
Trial: NCT03939884
Drug: Nivea, Topical Cream
RxNorm normalized name: Nivea, topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
Trial: NCT01797601
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin dilution medium without insulin
Trial: NCT01537029
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosed by the patient's treating physician according to local standard of care.
Trial: NCT01537029
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dosage form: IV, Dosage, frequency, and duration: According to local standard of care
Trial: NCT01964703
Drug: Rubus occidentalis extract
RxNorm normalized name: Rubus ursinus whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02467010
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets \> 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause.
Trial: NCT00115687
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00757757
Drug: MCS110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-M-CSF antibody
Trial: NCT04492020
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For each qualifying prodrome event, 2 compressed tablets containing placebo will be taken orally when the participant is confident that a headache will follow within 1-6 hours
Trial: NCT03858192
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment for infection and reason for admission
Trial: NCT00048204
Drug: GW597599B
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04790838
Drug: Test
RxNorm normalized name: Testro
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations of Test and Reference product in each study period
Trial: NCT04790838
Drug: Reference
RxNorm normalized name: Loreal Preference Dark Auburn 4R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations of Test and Reference product in each study period
Trial: NCT02075671
Drug: Aminolevulinic acid topical solution 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention used in the experimental arm only
Trial: NCT02517437
Drug: Suprascapular & axillary blocks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots to achieve circumferential spread around the nerve.The axillary nerve block will be performed next in the posterior aspect of the operative arm. The neurovascular bundle encompassing the humeral artery, posterior circumflex artery, and axillary nerve is visualized in the lateral edge of the quadrangular space, deep to the deltoid muscle, inferior to the teres minor muscle, and superior to the triceps tendon. After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots after negative aspiration to achieve circumferential spread around the bundle.
Trial: NCT02693093
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02963376
Drug: 0.17 mL/kg Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.17 mL/kg is based on patient body weight in kilograms (kg).
Trial: NCT01291017
Drug: PD0332991
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD0332991 125 mg PO days 1 - 21
Trial: NCT01330771
Drug: hMG-HP/r-FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04809935
Drug: 98% dehydrated alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * coeliac plexus is identified and punctured~* Injection of 10 mL of .25% bupivacaine, followed by 10 mL of 98% dehydrated alcohol.
Trial: NCT00649818
Drug: Ativan Tablets 2 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2mg, single dose fasting
Trial: NCT04580121
Drug: RO7283420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7283420 will be administered to participants by intravenous (IV) infusion Q3W at a starting dose of 0.15mg. Starting dose levels (double step-up regimen, Q3W) for SC injections was the same as the highest dose levels that have been cleared in the IV double step-up cohorts at that timepoint. Each participant will receive up to 6, 9, and 18 cycles of treatment with RO7283420, when treated with Q3W, Q2W, or QW dosing regimens, respectively.
Trial: NCT04580121
Drug: RO7283420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7283420 at RP2D will be administered by IV infusion or SC injection as per dosing schedule determined in Part B.
Trial: NCT04580121
Drug: Paracetamol/acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 or 1000 mg of paracetamol/acetaminophen will be administered orally or by IV as pre-medication at least 30 minutes prior to each RO7283420 infusion or injection.
Trial: NCT01775865
Drug: Salsalate
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 weeks of daily salsalate
Trial: NCT01775865
Drug: Placebo (for salsalate)
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 week of daily placebo
Trial: NCT01708590
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneous (SC)
Trial: NCT00760565
Drug: RO4905417
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3mg/kg iv every 28 days for 3 infusions
Trial: NCT00760565
Drug: RO4905417
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg/kg iv every 28 days for 3 infusions
Trial: NCT00760565
Drug: RO4905417
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7mg/kg iv every 28 days for 3 infusions
Trial: NCT00760565
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3mg/kg iv every 28 days for 3 infusions
Trial: NCT00760565
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7mg/kg iv every 28 days for 3 infusions
Trial: NCT00760565
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg/kg iv every 28 days for 3 infusions
Trial: NCT01805830
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
Trial: NCT00752830
Drug: AZD0328
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule, single dose
Trial: NCT01394952
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT01884428
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 100 mg on days 1 to 4 for a maximum of 4 cycles of three weeks duration
Trial: NCT01335997
Drug: ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet taken once daily
Trial: NCT01335997
Drug: Simvastatin (SIM)
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 10 mg oral tablet taken once daily
Trial: NCT01335997
Drug: Placebo Run-In
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matches both ER niacin 1 g/laropiprant 20 mg oral tablet and ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet; placebo is taken once daily
Trial: NCT01335997
Drug: SIM-matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for simvastatin 10 mg oral tablet taken once daily
Trial: NCT02289235
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo powder 2 capsules twice daily for 3 months
Trial: NCT00560430
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo; orally weeks 1-14
Trial: NCT00362921
Drug: Gliadel wafers in combination with O6-benzylguanine
RxNorm normalized name: O6-benzylguanine
DrugBank: 6-O-benzylguanine (DB11919)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00838708
Drug: SRD174 Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical SRD174 Cream